Anticipated 2025 Milestones: Part A data from GD2-SADA Phase 1 trial expected to be presented in the second quarter of 2025; GD2-SADA optimization data expected to be presented in the second quarter of 2025; Expect to present updates with respect to reprioritized SADA PRIT pipeline, including new high-value target indications and timelines, in the second quarter of 2025; Expect to dose first patient in CD38-SADA Phase 1 trial in the first quarter of 2025; Potential for marketing approval of DANYELZA in new ex-U.S. market in 2025; Plan to provide full year 2025 guidance in conjunction with full year 2024 earnings report in the first quarter of 2025
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
- Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
- Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential
- Y-mAbs Therapeutics initiated with a Buy at Brookline
- Y-mAbs Therapeutics initiated with an Outperform at Oppenheimer